“Healthy Skepticism” A New Ad Campaign from Lilly Against Compounded Drugs
Two blockbuster weight loss drugs including Lilly’s Zepbound were in U.S. FDA’s drugs shortage list.
Based on Results From the Phase 3 BRUIN CLL-321 trial, Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union
The European Commission is currently taking final action on the application for the use of Jaypirca in patients with relapsed or refractory CLL who have received prior treatment with a BTK inhibitor as a result of this favorable view.
Amyotrophic Lateral Sclerosis Can be Diagnosed With Blood Test
Three blood biomarker categories were evaluated in the study: phosphorylated tau 181, glial acidic proteins, and neurofilament light chain proteins.
Merck’s Application for KEYTRUDA® (pembrolizumab) Receives US FDA’s Priority Review
American pharma giant Merck’s application for KEYTRUDA® (pembrolizumab) receives US FDA’s priority review acceptance. Acceptance based on results from the KEYNOTE-689 trial. This is the [Read More…]
New Skin Disease was Discovered Using an Innovative Diagnostic Platform
Many Americans suffer from long-term inflammatory skin disorders that have no known etiology and frequently no effective treatments other than symptom control. A recent study [Read More…]
A Rare Side Effect for Cancer Immunotherapy Detected
The researchers found that the tumor was produced by more than only the T cells’ present genetic changes.
US FDA Approves Ctexli, First Treatment for Cerebrotendinous Xanthomatosis of Mirum Pharma
The first medication approved by the FDA to treat CTX, a rare lipid storage condition, is Ctexli.
Intriguing New Class of Antimalarial Drugs Discovered
A study team headed by Gernot Längst (University of Regensburg) and Markus Meißner (LMU Munich) has made significant progress in understanding the gene regulation of the malaria pathogen.
Positive Outcomes From the Initial Prenatal Therapy for Spinal Muscular Atrophy
Researchers at St. Jude Children’s Research Hospital report findings from a novel and promising treatment for the uncommon neurological disease.
Development of Innovative DNA Hydrogels for Assisted Drug Release
Utilizing reduced Takumi-shaped DNA nanostructures, researchers create optimal DNA hydrogels with possible biological uses.
